by Ketamine Greater Boston | Jan 3, 2021 | KETAMINE FOR DEPRESSION
In early 2019, the FDA approved esketamine (marketed as Spravato™) as an additional therapy option for the management of treatment-resistant depression. Like its parent compound, ketamine, Spravato aids in the restoration of synaptic connections in the brain, which is...
by Ketamine Greater Boston | Oct 1, 2019 | KETAMINE FOR DEPRESSION
Did you know that there are about 14 million people in the United States who struggle with a major depressive disorder at some point in their lives? Shocking, right? Well, even more incredible is that 30% of those people suffer from treatment-resistant depression:...
by Ketamine Greater Boston | Sep 26, 2019 | KETAMINE FOR DEPRESSION
Suicide claimed more than 47,000 lives in the United States in 2017. This frightening number represents the people who have lost all hope in themselves, and in their environments. The revolving door of failed antidepressants are likely a major contributor to their...
Recent Comments